2022
DOI: 10.1007/s10484-022-09575-x
|View full text |Cite|
|
Sign up to set email alerts
|

For Which Children with ADHD is TBR Neurofeedback Effective? Comorbidity as a Moderator

Abstract: Introduction: We examined psychiatric comorbidities moderation of a 2-site double-blind randomized clinical trial of theta/beta-ratio (TBR) neurofeedback (NF) for attention de cit hyperactivity disorder (ADHD).Methods:Seven-to-ten-year-olds with ADHD received either NF (n=84) or Control (n=58) for 38 treatments.Outcome was change in parent-/teacher-rated inattention from baseline to end-of-treatment (acute effect), and 13-month-follow-up. Seventy percent had at least one comorbidity: oppositional de ant disord… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 44 publications
0
1
0
Order By: Relevance
“…Specifically, both groups had large significant inattentive symptom improvements that were sustained for 21 months following treatment (The Neurofeedback Collaborative Group, 2023), without a significant difference between treatments. However, moderator analyses showed significant effects in comorbidity subgroups; at treatment end, those with comorbid anxiety without oppositional-defiant disorder (ODD) improved significantly more with the control treatment than with NF, and at 13-month follow-up, those with ODD without anxiety were significantly more improved with NF than control treatment (Roley-Roberts et al, 2023). Moreover, baseline cognitive signatures, quantified by applying computational modeling to the baseline neurocognitive data, indicated children who benefitted from receiving NF treatment (Ging-Jehli et al, 2023).…”
Section: The Present Studymentioning
confidence: 99%
“…Specifically, both groups had large significant inattentive symptom improvements that were sustained for 21 months following treatment (The Neurofeedback Collaborative Group, 2023), without a significant difference between treatments. However, moderator analyses showed significant effects in comorbidity subgroups; at treatment end, those with comorbid anxiety without oppositional-defiant disorder (ODD) improved significantly more with the control treatment than with NF, and at 13-month follow-up, those with ODD without anxiety were significantly more improved with NF than control treatment (Roley-Roberts et al, 2023). Moreover, baseline cognitive signatures, quantified by applying computational modeling to the baseline neurocognitive data, indicated children who benefitted from receiving NF treatment (Ging-Jehli et al, 2023).…”
Section: The Present Studymentioning
confidence: 99%